Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARGX-113 subcutaneous versus intravenous pharmacokinetics study in healthy male volunteers
NL-OMON46383Active, not recruiting
- Sponsor
- argenx
- Start
- Oct 2017
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of efgartigimod alfa in myasthenia gravis (MG) and immune thrombocytopenia (ITP) (4 arms), sponsored by argenx. Primary endpoint: AUC0-inf. Started Oct 2017; status: active, not recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NL-OMON46383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46383.